Deutsch English Français

Contact

EP3134087

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP3134087

EP3134087 - HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 22.01.2021 Database last updated on 11.04.2026
Former	The patent has been granted Status updated on 14.02.2020
Former	Grant of patent is intended Status updated on 23.09.2019
Former	Examination is in progress Status updated on 01.09.2017
Former	Request for examination was made Status updated on 27.01.2017
Former	The international publication has been made Status updated on 07.11.2016
Most recent event Tooltip	08.07.2022	Lapse of the patent in a contracting state New state(s): MK	published on 10.08.2022 [2022/32]
Applicant(s)	For all designated states Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US
	[2020/12]
Former [2017/09]	For all designated states Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US
Inventor(s)	01 / GRAY, David Lawrence Firman 26 Orion Way Groton, Massachusetts 01450 / US
	02 / ZHANG, Lei 75 Bourne Street Auburndale, Massachusetts 02466 / US
	03 / DAVOREN, Jennifer Elizabeth 2456 Massachusetts Avenue 105 Cambridge, Massachusetts 02140 / US
	04 / DOUNAY, Amy Beth 5725 Astoria Way Colorado Springs, Colorado 80919 / US
	05 / EFREMOV, Ivan Viktorovich 83 Payson Road Brookline, Massachusetts 02467 / US
	06 / MENTE, Scot Richard 48 Arlmont Street Arlington, Massachusetts 02476 / US
	07 / SUBRAMANYAM, Chakrapani 314 Great Pond Road South Glastonbury, Connecticut 06073 / US
	[2017/09]
Representative(s)	Cohausz & Florack Patent- & Rechtsanwälte Partnerschaftsgesellschaft mbB Bleichstraße 14 40211 Düsseldorf / DE
	[2020/12]
Former [2017/09]	Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR
Application number, filing date	15718387.2	09.04.2015
	[2017/09]
	WO2015IB52594
Priority number, date	US201461984070P	25.04.2014 Original published format: US 201461984070 P
	[2017/09]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2015162515
	Date:	29.10.2015
	Language:	EN
	[2015/43]
	Type:	A1 Application with search report
	No.:	EP3134087
	Date:	01.03.2017
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 29.10.2015 takes the place of the publication of the European patent application.
	[2017/09]
	Type:	B1 Patent specification
	No.:	EP3134087
	Date:	18.03.2020
	Language:	EN
	[2020/12]
Search report(s)	International search report - published on:	EP	29.10.2015
Classification	IPC:	A61K31/4355, A61K31/4365, A61K31/437, A61K31/497, A61K31/506, A61K31/513, A61K31/519, A61P25/16, A61P25/18, A61P25/24, A61P25/28, C07D471/04, C07D491/048, C07D495/04, C07D513/04, C07D519/00	[2017/09]
	CPC:	C07D519/00 (EP,CN,US); A61K31/519 (EP,CN,KR,US); A61K31/4355 (EP,CN,KR,US); A61K31/4365 (EP,CN,KR,US); A61K31/437 (EP,CN,KR,US); A61K31/497 (EP,CN,KR,US); (+) A61K31/4985 (EP,US); A61K31/506 (EP,CN,KR,US); A61K31/513 (EP,CN,US); A61P25/16 (EP,US); A61P25/18 (EP,US); A61P25/24 (EP,US); C07D471/04 (EP,KR,US); C07D491/048 (EP,KR,US); C07D491/147 (CN,US); C07D495/04 (EP,KR,US); C07D495/14 (EP,CN,US); C07D513/04 (EP,KR,US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/09]
Extension states	BA	25.11.2016
	ME	25.11.2016
Validation states	MA	25.11.2016
Title	German:	HETEROAROMATISCHE VERBINDUNGEN UND IHRE VERWENDUNG ALS DOPAMIN D1 LIGANDEN	[2019/39]
	English:	HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS	[2017/09]
	French:	COMPOSÉS HÉTÉROAROMATIQUES ET LEUR UTILISATION EN TANT QUE LIGANDS DU RÉCEPTEUR D1 DE LA DOPAMINE	[2019/39]
	Former [2017/09]	HETEROAROMATISCHE VERBINDUNGEN UND DEREN VERWENDUNG ALS DOPAMIN-D1-LIGANDEN
	Former [2017/09]	COMPOSÉS HÉTÉROAROMATIQUES ET LEUR UTILISATION COMME LIGANDS DE LA DOPAMINE D1
Entry into regional phase	25.11.2016	National basic fee paid
	25.11.2016	Designation fee(s) paid
	25.11.2016	Examination fee paid
Examination procedure	14.09.2015	Request for preliminary examination filed International Preliminary Examining Authority: EP
	07.11.2016	Amendment by applicant (claims and/or description)
	07.11.2016	Date on which the examining division has become responsible
	25.11.2016	Examination requested [2017/09]
	05.09.2017	Despatch of a communication from the examining division (Time limit: M04)
	18.12.2017	Reply to a communication from the examining division
	04.10.2018	Despatch of a communication from the examining division (Time limit: M04)
	31.01.2019	Reply to a communication from the examining division
	24.09.2019	Communication of intention to grant the patent
	04.02.2020	Fee for grant paid
	04.02.2020	Fee for publishing/printing paid
	04.02.2020	Receipt of the translation of the claim(s)
Opposition(s)	21.12.2020	No opposition filed within time limit [2021/08]
Fees paid	Renewal fee
	02.05.2017	Renewal fee patent year 03
	30.04.2018	Renewal fee patent year 04
	15.04.2019	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	09.04.2015
	AL	18.03.2020
	AT	18.03.2020
	CY	18.03.2020
	CZ	18.03.2020
	DK	18.03.2020
	EE	18.03.2020
	ES	18.03.2020
	FI	18.03.2020
	HR	18.03.2020
	IT	18.03.2020
	LT	18.03.2020
	LV	18.03.2020
	MC	18.03.2020
	MK	18.03.2020
	MT	18.03.2020
	NL	18.03.2020
	PL	18.03.2020
	RO	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	SI	18.03.2020
	SK	18.03.2020
	SM	18.03.2020
	TR	18.03.2020
	LU	09.04.2020
	BE	30.04.2020
	CH	30.04.2020
	LI	30.04.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
	IS	18.07.2020
	PT	12.08.2020
	[2022/31]
Former [2022/30]	HU	09.04.2015
	AL	18.03.2020
	AT	18.03.2020
	CY	18.03.2020
	CZ	18.03.2020
	DK	18.03.2020
	EE	18.03.2020
	ES	18.03.2020
	FI	18.03.2020
	HR	18.03.2020
	IT	18.03.2020
	LT	18.03.2020
	LV	18.03.2020
	MC	18.03.2020
	MT	18.03.2020
	NL	18.03.2020
	PL	18.03.2020
	RO	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	SI	18.03.2020
	SK	18.03.2020
	SM	18.03.2020
	TR	18.03.2020
	LU	09.04.2020
	BE	30.04.2020
	CH	30.04.2020
	LI	30.04.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
	IS	18.07.2020
	PT	12.08.2020
Former [2022/27]	HU	09.04.2015
	AT	18.03.2020
	CY	18.03.2020
	CZ	18.03.2020
	DK	18.03.2020
	EE	18.03.2020
	ES	18.03.2020
	FI	18.03.2020
	HR	18.03.2020
	IT	18.03.2020
	LT	18.03.2020
	LV	18.03.2020
	MC	18.03.2020
	MT	18.03.2020
	NL	18.03.2020
	PL	18.03.2020
	RO	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	SI	18.03.2020
	SK	18.03.2020
	SM	18.03.2020
	TR	18.03.2020
	LU	09.04.2020
	BE	30.04.2020
	CH	30.04.2020
	LI	30.04.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
	IS	18.07.2020
	PT	12.08.2020
Former [2021/24]	AT	18.03.2020
	CZ	18.03.2020
	DK	18.03.2020
	EE	18.03.2020
	ES	18.03.2020
	FI	18.03.2020
	HR	18.03.2020
	IT	18.03.2020
	LT	18.03.2020
	LV	18.03.2020
	MC	18.03.2020
	NL	18.03.2020
	PL	18.03.2020
	RO	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	SI	18.03.2020
	SK	18.03.2020
	SM	18.03.2020
	LU	09.04.2020
	BE	30.04.2020
	CH	30.04.2020
	LI	30.04.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
	IS	18.07.2020
	PT	12.08.2020
Former [2021/10]	AT	18.03.2020
	CZ	18.03.2020
	DK	18.03.2020
	EE	18.03.2020
	ES	18.03.2020
	FI	18.03.2020
	HR	18.03.2020
	IT	18.03.2020
	LT	18.03.2020
	LV	18.03.2020
	MC	18.03.2020
	NL	18.03.2020
	PL	18.03.2020
	RO	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	SK	18.03.2020
	SM	18.03.2020
	LU	09.04.2020
	BE	30.04.2020
	CH	30.04.2020
	LI	30.04.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
	IS	18.07.2020
	PT	12.08.2020
Former [2021/09]	AT	18.03.2020
	CZ	18.03.2020
	DK	18.03.2020
	EE	18.03.2020
	ES	18.03.2020
	FI	18.03.2020
	HR	18.03.2020
	IT	18.03.2020
	LT	18.03.2020
	LV	18.03.2020
	MC	18.03.2020
	NL	18.03.2020
	RO	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	SK	18.03.2020
	SM	18.03.2020
	LU	09.04.2020
	CH	30.04.2020
	LI	30.04.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
	IS	18.07.2020
	PT	12.08.2020
Former [2021/08]	CZ	18.03.2020
	DK	18.03.2020
	EE	18.03.2020
	ES	18.03.2020
	FI	18.03.2020
	HR	18.03.2020
	LT	18.03.2020
	LV	18.03.2020
	MC	18.03.2020
	NL	18.03.2020
	RO	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	SK	18.03.2020
	SM	18.03.2020
	LU	09.04.2020
	CH	30.04.2020
	LI	30.04.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
	IS	18.07.2020
	PT	12.08.2020
Former [2021/07]	CZ	18.03.2020
	DK	18.03.2020
	EE	18.03.2020
	FI	18.03.2020
	HR	18.03.2020
	LT	18.03.2020
	LV	18.03.2020
	MC	18.03.2020
	NL	18.03.2020
	RO	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	SK	18.03.2020
	SM	18.03.2020
	CH	30.04.2020
	LI	30.04.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
	IS	18.07.2020
	PT	12.08.2020
Former [2021/04]	CZ	18.03.2020
	EE	18.03.2020
	FI	18.03.2020
	HR	18.03.2020
	LT	18.03.2020
	LV	18.03.2020
	MC	18.03.2020
	NL	18.03.2020
	RO	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	SK	18.03.2020
	SM	18.03.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
	IS	18.07.2020
	PT	12.08.2020
Former [2020/50]	CZ	18.03.2020
	EE	18.03.2020
	FI	18.03.2020
	HR	18.03.2020
	LT	18.03.2020
	LV	18.03.2020
	NL	18.03.2020
	RO	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	SK	18.03.2020
	SM	18.03.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
	IS	18.07.2020
	PT	12.08.2020
Former [2020/49]	CZ	18.03.2020
	FI	18.03.2020
	HR	18.03.2020
	LT	18.03.2020
	LV	18.03.2020
	NL	18.03.2020
	RO	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	SK	18.03.2020
	SM	18.03.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
	IS	18.07.2020
	PT	12.08.2020
Former [2020/48]	FI	18.03.2020
	HR	18.03.2020
	LT	18.03.2020
	LV	18.03.2020
	NL	18.03.2020
	RO	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	SM	18.03.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
	IS	18.07.2020
	PT	12.08.2020
Former [2020/47]	FI	18.03.2020
	HR	18.03.2020
	LT	18.03.2020
	LV	18.03.2020
	NL	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
	IS	18.07.2020
Former [2020/46]	FI	18.03.2020
	HR	18.03.2020
	LV	18.03.2020
	NL	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
	IS	18.07.2020
Former [2020/45]	FI	18.03.2020
	HR	18.03.2020
	LV	18.03.2020
	NL	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
Former [2020/39]	FI	18.03.2020
	HR	18.03.2020
	LV	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	BG	18.06.2020
	NO	18.06.2020
	GR	19.06.2020
Former [2020/38]	FI	18.03.2020
	HR	18.03.2020
	LV	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	NO	18.06.2020
	GR	19.06.2020
Former [2020/37]	FI	18.03.2020
	HR	18.03.2020
	LV	18.03.2020
	RS	18.03.2020
	SE	18.03.2020
	NO	18.06.2020
Former [2020/35]	FI	18.03.2020
	NO	18.06.2020
Cited in	International search	[XD] CN102558147 (JIANGSU SIMCERE PHARM RES CO et al.)
		[X] WO2005110410 (ABBOTT LAB et al.)
		[X] WO2009079412 (ARDEA BIOSCIENCES INC et al.)
		[X] DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1 January 1997 (1997-01-01), ABOU- ZEID, K. A. M. ET AL: "Synthesis of 6-(4-(substituted amino)phenyl)-4,5-dihydropyridazin-3(2H)-ones as potential positive", XP002741084, retrieved from STN Database accession no. 1999:458499
		[I] JING ZHANG ET AL: "Dopamine D 1 receptor ligands: Where are we now and where are we going", MEDICINAL RESEARCH REVIEWS, vol. 29, no. 2, 1 March 2009 (2009-03-01), pages 272 - 294, XP055196414, ISSN: 0198-6325, DOI: 10.1002/med.20130 DOI: http://dx.doi.org/10.1002/med.20130
	by applicant	WO2013026516
		US2012329780
		CN102558147
		US2012022090
		US2010056548
		WO2007009524
		US2005153989
		US6106864
		WO0035298
		WO9111172
		WO9402518
		WO9855148
		US5322847
		MISSALE C; NASH SR; ROBINSON SW; JABER M; CARON MG: "Dopamine receptors: from structure to function", PHYSIOLOGICAL REVIEWS, vol. 78, 1998, pages 189 - 225
		GOLDMAN-RAKIC PS ET AL.: "Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction", PSYCHOPHARMACOLOGY, vol. 174, no. 1, 2004, pages 3 - 16
		GOULET M; MADRAS BK: "D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPY, vol. 292, no. 2, 2000, pages 714 - 24
		SURMEIER DJ ET AL.: "The role of dopamine in modulating the structure and function of striatal circuits", PROG. BRAIN RES., vol. 183, 2010, pages 149 - 67
		ABOU-ZEID, K. A. M. ET AL.: "synthesis of 6-(4-(substituted amino)phenyl)-4,5-dihydropyridazin-3(2H)-ones as potential positive inotropic agents", EGYPTIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 38, no. 4-6, 1997, pages 319 - 331
		STAHL; WERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH
		O. ALMARSSON; M. J. ZAWOROTKO, CHEM. COMMUN., vol. 17, 2004, pages 1889 - 1896
		J. K. HALEBLIAN, J. PHARM. SCI., vol. 64, 1975, pages 1269 - 1288
		N. H. HARTSHORNE; A. STUART: "Crystals and the Polarizing Microscope", 1970
		T. HIGUCHI; W. STELLA: "Pro-drugs as Novel Delivery Systems", vol. 14, ACS SYMPOSIUM SERIES
		"Bioreversible Carriers in Drug Design", 1987, PERGAMON PRESS
		H. BUNDGAARD: "Design of Prodrugs", 1985, ELSEVIER
		"Prodrugs: Challenges and Reward", 2007, SPRINGER, pages: 134 - 175
		FREEDMAN, T. B. ET AL.: "Absolute Configuration Determination of Chiral Molecules in the Solution State Using Vibrational Circular Dichroism", CHIRALITY, vol. 15, 2003, pages 743 - 758
		BRINGMANN, G. ET AL.: "Atroposelective Synthesis of Axially Chiral Biaryl Compounds", ANGEW. CHEM., INT. ED., vol. 44, 2005, pages 5384 - 5427, XP055022810, DOI: doi:10.1002/anie.200462661 DOI: http://dx.doi.org/10.1002/anie.200462661
		LEWIS, JPET, vol. 286, 1998, pages 345 - 353
		T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY & SONS, INC.
		A. SUZUKI, J. ORGANOMET. CHEM., vol. 576, 1999, pages 147 - 168
		N. MIYAURA; A. SUZUKI, CHEM. REV., vol. 95, 1995, pages 2457 - 2483
		A. F. LITTKE ET AL., J. AM. CHEM. SOC., vol. 122, 2000, pages 4020 - 4028
		V. FARINA ET AL., ORGANIC REACTIONS, vol. 50, 1997, pages 1 - 652
		E. ERDIK, TETRAHEDRON, vol. 48, 1992, pages 9577 - 9648
		E. L. ELIEL; S. H. WILEN: "Stereochemistry of Organic Compounds", 1994, WILEY
		"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
		LIANG; CHEN, EXPERT OPINION IN THERAPEUTIC PATENTS, vol. 11, 2001, pages 981 - 986
		H. LIEBERMAN; L. LACHMAN: "Pharmaceutical Dosage Forms: Tablets", vol. 1, 1980, MARCEL DEKKER
		VERMA ET AL., PHARMACEUTICAL TECHNOLOGY ON-LINE, vol. 25, no. 2, 2001, pages 1 - 14
		FINNIN; MORGAN, J. PHARM. SCI., vol. 88, 1999, pages 955 - 958
		D. KALAITZAKIS ET AL., TETRAHEDRON: ASYMMETRY, vol. 18, 2007, pages 2418 - 2426
		S. L. BUCHWALD ET AL., J. AM. CHEM. SOC., vol. 132, 2010, pages 14073 - 14075
		A. R. HARRIS ET AL., TETRAHEDRON, vol. 67, 2011, pages 9063 - 9066
		RYMAN-RASMUSSEN ET AL.: "Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists", MOLECULAR PHARMACOLOGY, vol. 68, no. 4, 2005, pages 1 039 - 1 048

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.